MYGN

Myriad Genetics, Inc.

A molecular diagnostics company, Myriad Genetics makes genetic tests that doctors order to gauge hereditary cancer risk, guide drug choices, and screen for prenatal and mental-health conditions. Founded in Salt Lake City in 1991 by a University of Utah geneticist, it became famous for sequencing and patenting the BRCA1 and BRCA2 breast-cancer genes, launching its first test in 1996. The name "myriad" hints at the countless gene possibilities the company explores, and its early gene patents were struck down by the Supreme Court in 2013.